GlassScriptPhysician profile
Lisa L Kozel
NPI 1487692661
$587.42
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $146 · 2021: $180 · 2022: $13.95.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $227.55 | 2019-2021 | |
| Glaxosmithkline, LLC. | $77.59 | 2020-2021 | |
| Novo Nordisk INC | $72.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $42.42 | 2019-2020 | |
| Pfizer INC. | $39.73 | 2019-2020 | |
| Lilly USA, LLC | $36.71 | 2019 | |
| Grifols USA, LLC | $23.99 | 2019 | |
| Pacira Therapeutics, INC. | $21.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.68 | 2019 | |
| Sanofi Pasteur INC. | $15.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.95 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Kozel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.